Kadimastem Ltd Market Cap ($22.18 Million)
Market Cap & Net Worth: Kadimastem Ltd (KDST)
Kadimastem Ltd market cap. Kadimastem Ltd (TA:KDST) has a market capitalization of $22.18 Million (ILA8.27 Billion) as of November 1, 2026. Listed on the TA stock exchange, this Israel-based company holds position #24647 globally and #353 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kadimastem Ltd's stock price ILA2794.00 by its total outstanding shares 2960744 (2.96 Million). Also see cash efficiency ratio of Kadimastem Ltd for how efficiently the company converts equity into cash flow.
Kadimastem Ltd Market Cap History (2015–2025)
Kadimastem Ltd market cap history from 2015 to 2025. Data shows change from $494.37 Million to $22.18 Million (-22.73% CAGR). Check current stock price of Kadimastem Ltd for real-time trading data and today's change.
Kadimastem Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kadimastem Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Kadimastem Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
53.43x
Kadimastem Ltd's market cap is 53.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $494.37 Million | $1.03 Million | -$17.06 Million | 480.91x | N/A |
| 2016 | $424.19 Million | $1.70 Million | -$19.97 Million | 249.09x | N/A |
| 2017 | $36.55 Million | $684.00K | -$21.43 Million | 53.43x | N/A |
Competitor Companies of KDST by Market Capitalization
Companies near Kadimastem Ltd in the global market cap rankings as of November 1, 2026. Also see how large is Kadimastem Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Kadimastem Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Kadimastem Ltd (2015–2025)
Market capitalization of Kadimastem Ltd from 2015 to today. Between 2015 and today, Kadimastem Ltd's market cap moved from $494.37 Million to $ 22.18 Million, with a yearly change of -22.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ILA22.18 Million | +115.75% |
| 2024 | ILA10.28 Million | +116.56% |
| 2023 | ILA4.75 Million | -50.17% |
| 2022 | ILA9.53 Million | -65.10% |
| 2021 | ILA27.30 Million | +73.65% |
| 2020 | ILA15.72 Million | -60.96% |
| 2019 | ILA40.27 Million | -31.76% |
| 2018 | ILA59.01 Million | +61.44% |
| 2017 | ILA36.55 Million | -91.38% |
| 2016 | ILA424.19 Million | -14.20% |
| 2015 | ILA494.37 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 29th, 2026 the market cap of Kadimastem Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.18 Million USD |
| MoneyControl | $22.18 Million USD |
| MarketWatch | $22.18 Million USD |
| marketcap.company | $22.18 Million USD |
| Reuters | $22.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more